List of publications using AZD 7762 (Axon 1399) purchased from Axon Medchem

(total 29 publications from 2009-2015)

BRCA2 is needed for both repair and cell cycle arrest in mammalian cells exposed to S23906, an anticancer monofunctional DNA binder.
CJ Rocca, DG Soares, H Bouzid, JAP Henriques, AK Larsen & AE Escargueil.
Cell Cycle, 2015, in press. DOI:10.1080/15384101.2015.1042632

Novel Role of CHK2 in the Intrinsic and Extrinsic Apoptosis Pathway.
Anurag Agarwal, 2014 PhD Thesis of Washington University in St. Louis.

Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
C Bryant, R Rawlinson, AJ Massey - 
BMC Cancer 2014, 14:570. 

Checkpoint Kinase Inhibitor AZD7762 Overcomes Cisplatin Resistance in Clear Cell Carcinoma of the Ovary. 
Itamochi, H., Nishimura, M., Oumi, N., Kato, M., Oishi, T., Shimada, M., ... & Harada, T. 
Int. J. Gynecol. Cancer, 2014, 24(1), 61-69.

EGF Receptor activates MET through MAP kinases to enhance non-small cell lung carcinoma invasion and brain metastasis. 
JL Breindel, JW Haskins, EP Cowell, M Zhao, DX Nguyen & DF Stern. 
Cancer Res. June 21, 2013. doi: 10.1158/0008-5472.CAN-12-3775

CRL4CDT2 Targets CHK1 for PCNA-Independent Destruction.
J Huh, and H Piwnica-Worms.
Mol. Cell. Biol. 2013, 33(2), 213-226. doi: 10.1128/MCB.00847-12

Dissecting cellular responses to irradiation via targeted disruptions of the ATM-CHK1-PP2A circuit.
SS Palii, Y Cui, CL Innes and RS Paules.
Cell Cycle 2013, 12 (7), 1105-1108.

DW-MRI as a Predictive Biomarker of Radiosensitization of GBM through Targeted Inhibition of Checkpoint Kinases.
TM Williams, S Galbán, F Li, KA Heist, CJ Galbán, TS Lawrence, EC Holland, TL Thomae, TL Chenevert, A Rehemtulla, and BD Ross.
Transl. Oncol. 2013, 6(2), 133–142. PMCID: PMC3610547

PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells.
L Booth, N Cruickshanks, T Ridder, Y Dai, S Grant and P Dent.
Landes Biosci. 2013, 14 (5), 458-465.

Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells.
S Origanti, S Cai, AZ Munir, LS White, H Piwnica-Worms. - nature.com – 
Oncogene 2013, 32, 577–588; doi: 10.1038/onc.2012.84

Individualized Systems Medicine (ISM) strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. 
Pemovska, T., Kontro, M., Yadav, B., Edgren, H., Eldfors, S., Szwajda, A., ... & Wennerberg, K. 
Cancer discovery, 2013, CD-13.  doi: 10.1158/2159-8290.CD-13-0350

(18 publications extracted from 2009 to 2012) 
Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival.
JM Wagner, LM. Karnitz.
Mol. Pharmacol. 2009, 76(1), 208-214.  DOI: 10.1124/mol.109.055178

Casein kinase 1 functions as both penultimate and ultimate kinase in regulating Cdc25A destruction.
Y Honaker, H Piwnica-Worms. - nature.com – 
Oncogene, 2010, 29, 3324–3334.  DOI:10.1038/onc.2010.96

Poly(ADP-Ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Carcinoma Cells.
C Mitchell, M Park, P Eulitt, C Yang, A Yacoub and P Dent
Mol. Pharmacol. 2010, 78 (5), 909-917. DOI: 10.1124/mol.110.067199

Role of Chk1 in the differentiation program of hematopoietic stem cells.
L Carrassa, E Montelatici, L Lazzari, S Zangrossi, M Simone, M Broggini, G Damia
Cell. Mol. Life Sci. 2010, 67 (10), 1713-1722. DOI: 10.1007/s00018-010-0274-1

Inhibition of checkpoint kinase 1 sensitizes lung cancer brain metastases to radiotherapy.
H Yang, SJ Yoon, J Jin, SH Choi, HJ Seol, JI Lee, DH Nam, HY Yoo.
Biochem. Biophys. Res. Comm. 2011, 406 (1), 53–58.

Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors.
JH Lee, ML Choy, L Ngo, G Venta-Perez, PA Marks.
PNAS, 2011, 108 (49), 19629-19634.  DOI: 10.1073/pnas.1117544108

Ataxia telangiectasia mutated- and Rad3-related kinase drives both the early and the late DNA-damage response to the monofunctional antitumour alkylator S23906.
DG Soares, A Battistella, CJ Rocca, R Matuo, JAP Henriques, AK Larsen, AE Escargueil.
Biochem. J. 2011, 437, 63–73.

Chk2 deficiency in Myc-overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition
A Höglund, K Strömvall, Y Li, LP Forshell, JA Nilsson.
Cell Cycle. 2011, 10(20), 3598–3607.  DOI:  10.4161/cc.10.20.17887

Checkpoint Kinase 1 Prevents Cell Cycle Exit Linked to Terminal Cell Differentiation.
Z Ullah, C de Renty, ML DePamphilis.
Mol. Cell. Biol., 2011, 31 (19), 4129-4143.  DOI: 10.1128/MCB.05723-11

In vitro and in vivo inhibition of Chk1 sensitize lung cancer stem cells to chemotherapy.
Susanne Svensson
PhD Thesis 2011, Università degli Studi di Catania, Italy.

Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. 
M Bartucci, S Svensson, P Romania, R Dattilo, M Patrizii, M Signore, S Navarra, F Lotti, M Biffoni, E Pilozzi, E Duranti, S Martinelli, C Rinaldo, A Zeuner, M Maugeri-Saccà, A Eramo and R De Maria.
Cell Death & Differentiation, 2011, 19(5), 768-778.

PARP Inhibitors Synergize With Loss of Checkpoint Control to Kill Mammary Carcinoma Cells.
P Dent, Y Tang - 2011
DTIC Document

Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype.
F Ricci, S Bernasconi, P Perego, M Ganzinelli, G Russo, F Bono, C Mangioni, R Fruscio, M Signorelli, M Broggini, G Damia.
Cell Cycle. 2012, 11 (10), 1966-1976. 

Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy.
M Bartucci, S Svensson, P Romania, R Dattilo, M Patrizii, M Signore, S Navarra, F Lotti, M Biffoni, E Pilozzi, E Duranti, S Martinelli, C Rinaldo, A Zeuner, M Maugeri-Saccà, A Eramo and R De Maria.  – nature.com – 
Cell Death & Differ. 2012, 19, 768–778.  DOI:10.1038/cdd.2011.170

Okazaki Fragment Processing-independent Role for Human Dna2 Enzyme during DNA Replication.
JP Duxin, HR Moore, J Sidorova, K Karanja, Y Honaker, B Dao, H Piwnica-Worms, JL Campbell, RJ Monnat Jr. and SA Stewart.
J Biol. Chem. 2012, 287, 21980-21991.  DOI: 10.1074/jbc.M112.359018

Poly(ADP-ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Mammary Tumors.
Y Tang, HA Hamed, A Poklepovic, Y Dai, S Grant and P Dent.
Mol. Pharmacol. 2012, 82(2), 322-332.  DOI: 10.1124/mol.112.078907

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
CX Ma, S Cai, S Li, CE Ryan, Z Guo, WT Schaiff, L Lin, J Hoog, RJ Goiffon, A Prat, RL Aft, MJ Ellis, H Piwnica-Worms.
J Clin Invest. 2012, 122(4), 1541–1552. doi: 10.1172/JCI58765  PMCID: PMC3314455


(This is an incomplete list, created on 01-JUN-2015) 

 

Please wait...